SciBase and Castle Biosciences Enhance Strategic Partnership
SciBase Holding AB (STO: SCIB), a distinguished leader in developing AI-driven diagnostic solutions for skin conditions, has announced an expansion of its collaboration with Castle Biosciences (NASDAQ: CSTL). This expanded agreement furthers their initial partnership formed in June 2025, enhancing the scope and impact of their work in dermatology.
New Developments in Collaboration
The latest collaboration milestone involves Castle Biosciences gaining greater autonomy over the manufacturing processes of their innovative diagnostic products. This strategic shift aims to streamline production efficiency while ensuring high-quality outputs for both companies.
A Focus on Atopic Dermatitis
The primary target of their joint efforts is to conduct clinical studies aimed at developing a predictive test for flare-ups in patients suffering from atopic dermatitis. Through this research, they hope to identify additional indications for future applications of the technology, enhancing therapeutic strategies in dermatology.
Loan Agreement Details
The companies have also entered into a separate loan agreement amounting to SEK 20 million, which will provide SciBase with necessary financial resources. This loan is structured as a five-year commitment, where Castle is set to charge an interest rate based on STIBOR plus an additional two percent annually. The initial interest payment is scheduled for March 31, 2026.
Pia Renaudin, CEO of SciBase, expressed enthusiasm regarding this collaboration, stating, "Our partnership with Castle Biosciences is moving ahead at full speed. With this financial backing, we aim to enhance our production capabilities and support our aggressive growth strategy. The anticipated increase in product margins will be beneficial across all markets and aid the wider adoption of Nevisense in skin health management."
Implications of the Loan Agreement
This loan not only strengthens the financial foundation of SciBase but also offers options for Castle to convert the loan into shares, providing strategic flexibility. This could occur during the five-year period following the signing of the agreement, with terms established around the shared stock price calculations.
The support from Castle through this financial arrangement underscores the commitment both companies have towards advancing the field of skin diagnostics. A secured share pledge on SciBase’s shares backs the loan agreement, ensuring a robust financial structure is in place.
About Castle Biosciences
Castle Biosciences is renowned in the diagnostics industry for its innovative testing capabilities which enhance patient care. Their portfolio includes various tests for skin cancers, Barrett's esophagus, and uveal melanoma, with ongoing research aimed at addressing other vital health conditions.
Ongoing projects for Castle include developing diagnostic tools for systemic treatment decisions for those affected by moderate-to-severe atopic dermatitis, indicative of the company's proactive approach to addressing high-demand clinical needs.
Growing Presence of SciBase in Dermatology
SciBase has established itself as a key player in medical technology with a focus on early detection and prevention in dermatology. Nevisense, their flagship product, integrates artificial intelligence with advanced electrical impedance spectroscopy to improve diagnostic accuracy and, ultimately, patient outcomes.
With a firm commitment to advancing healthcare, SciBase aims to reduce suffering and save lives through timely dermatological interventions, thereby optimizing healthcare resources. Established from pioneering research over 20 years at the Karolinska Institute in Stockholm, SciBase continues to lead in dermatological innovation.
The company has operated on the Nasdaq First North Growth Market since June 2015 and partners with Carnegie Investment Bank AB (publ) as its Certified Advisor.
Frequently Asked Questions
What is the focus of the partnership between SciBase and Castle Biosciences?
The partnership primarily aims to enhance the development of diagnostic tests for skin disorders, specifically focusing on atopic dermatitis.
What is the significance of the loan agreement?
The SEK 20 million loan agreement provides crucial funding for SciBase, enabling improved production capacity and growth support in the dermatology sector.
What technologies does Nevisense incorporate?
Nevisense employs AI and advanced electrical impedance spectroscopy technology to assist in the accurate diagnosis of skin conditions.
How does Castle Biosciences contribute to patient care?
Castle Biosciences develops innovative diagnostic tests aimed at transforming patient care and improving disease management.
When was SciBase founded, and what is its focus?
SciBase was founded over 20 years ago, focusing on early detection and prevention in dermatology, specifically through innovations in diagnostic technologies.
